1. Home
  2. CLLS vs MPA Comparison

CLLS vs MPA Comparison

Compare CLLS & MPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLLS
  • MPA
  • Stock Information
  • Founded
  • CLLS 1999
  • MPA 1992
  • Country
  • CLLS France
  • MPA United States
  • Employees
  • CLLS N/A
  • MPA N/A
  • Industry
  • CLLS Biotechnology: Pharmaceutical Preparations
  • MPA Finance Companies
  • Sector
  • CLLS Health Care
  • MPA Finance
  • Exchange
  • CLLS Nasdaq
  • MPA Nasdaq
  • Market Cap
  • CLLS 299.0M
  • MPA 148.2M
  • IPO Year
  • CLLS 2007
  • MPA N/A
  • Fundamental
  • Price
  • CLLS $3.95
  • MPA $11.40
  • Analyst Decision
  • CLLS Buy
  • MPA
  • Analyst Count
  • CLLS 1
  • MPA 0
  • Target Price
  • CLLS $8.00
  • MPA N/A
  • AVG Volume (30 Days)
  • CLLS 224.4K
  • MPA 25.2K
  • Earning Date
  • CLLS 11-03-2025
  • MPA 01-01-0001
  • Dividend Yield
  • CLLS N/A
  • MPA 3.83%
  • EPS Growth
  • CLLS N/A
  • MPA N/A
  • EPS
  • CLLS N/A
  • MPA N/A
  • Revenue
  • CLLS $63,438,000.00
  • MPA N/A
  • Revenue This Year
  • CLLS N/A
  • MPA N/A
  • Revenue Next Year
  • CLLS $66.76
  • MPA N/A
  • P/E Ratio
  • CLLS N/A
  • MPA N/A
  • Revenue Growth
  • CLLS 223.09
  • MPA N/A
  • 52 Week Low
  • CLLS $1.10
  • MPA $9.87
  • 52 Week High
  • CLLS $5.48
  • MPA $12.21
  • Technical
  • Relative Strength Index (RSI)
  • CLLS 55.93
  • MPA 55.91
  • Support Level
  • CLLS $3.93
  • MPA $11.33
  • Resistance Level
  • CLLS $5.48
  • MPA $11.49
  • Average True Range (ATR)
  • CLLS 0.40
  • MPA 0.12
  • MACD
  • CLLS 0.01
  • MPA -0.01
  • Stochastic Oscillator
  • CLLS 39.69
  • MPA 60.75

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About MPA Blackrock MuniYield Pennsylvania Quality Fund

Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with an investment objective to provide shareholders with as high a level of current income exempt from U.S. federal and Pennsylvania income taxes as is consistent with its investment policies and prudent investment management. The Fund seeks to achieve its investment objective by investing, as a fundamental policy, at least 80% of an aggregate of the Fund's net assets and the proceeds of any borrowings for investment purposes, in a portfolio of municipal obligations issued by or on behalf of the State of Pennsylvania, its political subdivisions, agencies, and instrumentalities and by other qualifying issuers.

Share on Social Networks: